Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 2/2016

01-02-2016 | Original Article

Screening or Symptoms? How Do We Detect Colorectal Cancer in an Equal Access Health Care System?

Authors: Quinton M. Hatch, Kevin R. Kniery, Eric K. Johnson, Shelly A. Flores, David L. Moeil, John J. Thompson, Justin A. Maykel, Scott R. Steele

Published in: Journal of Gastrointestinal Surgery | Issue 2/2016

Login to get access

Abstract

Background

Detection of colorectal cancer ideally occurs at an early stage through proper screening. We sought to establish methods by which colorectal cancers are diagnosed within an equal access military health care population and evaluate the correlation between TNM stage at colorectal cancer diagnosis and diagnostic modality (i.e., symptomatic detection vs screen detection).

Materials and Methods

A retrospective chart review of all newly diagnosed colorectal cancer patients from January 2007 to August 2014 was conducted at the authors’ equal access military institution. We evaluated TNM stage relative to diagnosis by screen detection (fecal occult blood test, flexible sigmoidoscopy, CT colonography, colonoscopy) or symptomatic evaluation (diagnostic colonoscopy or surgery).

Results

Of 197 colorectal cancers diagnosed (59 % male; mean age 62 years), 50 (25 %) had stage I, 47 (24 %) had stage II, 70 (36 %) had stage III, and 30 (15 %) had stage IV disease. Twenty-five percent of colorectal cancers were detected via screen detection (3 % by fecal occult blood testing (FOBT), 0.5 % by screening CT colonography, 17 % by screening colonoscopy, and 5 % by surveillance colonoscopy). One hundred forty-eight (75 %) were diagnosed after onset of signs or symptoms. The preponderance of these was advanced-stage disease (stages III–IV), although >50 % of stage I–II disease also had signs or symptoms at diagnosis. The most common symptoms were rectal bleeding (45 %), abdominal pain (35 %), and change in stool caliber (27 %). The most common overall sign was anemia (60 %). Screening FOBT (odds ratio (OR) 8.7, 95 % confidence interval (CI) 1.0–78.3; P = 0.05) independently predicted early diagnosis with stage I–II disease. Patient gender and ethnicity were not associated with cancer stage at diagnosis.

Conclusions

Despite equal access to colorectal cancer screening, diagnosis after development of symptomatic cancer remains more common. Fecal occult blood screen detection is associated with early stage at colorectal cancer diagnosis and is the focus for future initiatives.
Literature
1.
2.
3.
go back to reference Winawer S, Zauber A, Ho M, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977–81.CrossRefPubMed Winawer S, Zauber A, Ho M, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977–81.CrossRefPubMed
4.
go back to reference Selby J, Friedman J, Quesenberry CJ, Weiss N. A case–control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653–7.CrossRefPubMed Selby J, Friedman J, Quesenberry CJ, Weiss N. A case–control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653–7.CrossRefPubMed
5.
go back to reference Edwards B, Ward E, Kohler B, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–73.PubMedCentralCrossRefPubMed Edwards B, Ward E, Kohler B, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–73.PubMedCentralCrossRefPubMed
6.
go back to reference Yang D, Gross C, Soulos P, Yu J. Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. Cancer. 2014;120(18):2893–901.CrossRefPubMed Yang D, Gross C, Soulos P, Yu J. Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. Cancer. 2014;120(18):2893–901.CrossRefPubMed
7.
go back to reference Amri R, Bordeianou L, Sylla P, Berger D. Impact of screening colonoscopy on outcomes in colon cancer surgery. JAMA Surg. 2013;148(8):747–54.CrossRefPubMed Amri R, Bordeianou L, Sylla P, Berger D. Impact of screening colonoscopy on outcomes in colon cancer surgery. JAMA Surg. 2013;148(8):747–54.CrossRefPubMed
8.
go back to reference Alexiusdottir K, Moller P, Snaebjornsson P, et al. Association of symptoms of colon cancer patients with tumor location and TNM tumor stage. Scand J Gastroenterol. 2012;47:795–801.CrossRefPubMed Alexiusdottir K, Moller P, Snaebjornsson P, et al. Association of symptoms of colon cancer patients with tumor location and TNM tumor stage. Scand J Gastroenterol. 2012;47:795–801.CrossRefPubMed
9.
go back to reference Force USPST. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627–37.CrossRef Force USPST. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627–37.CrossRef
10.
go back to reference Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124(2):544–60.CrossRefPubMed Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124(2):544–60.CrossRefPubMed
11.
go back to reference Zauber A, Landsdorp-Vogelaar I, Knudsen A, et al. Age to begin, age to end, and timing of screening intervals: decision analysis of colorectal cancer screening for the United States Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling Network (CISNET). Evidence Synthesis No. 65, Part 2. AHRQ publication No. 08-05124-EF-2. Rockville, MD: Agency for Healthcare and Research Quality; Oct 2008. 2008. Zauber A, Landsdorp-Vogelaar I, Knudsen A, et al. Age to begin, age to end, and timing of screening intervals: decision analysis of colorectal cancer screening for the United States Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling Network (CISNET). Evidence Synthesis No. 65, Part 2. AHRQ publication No. 08-05124-EF-2. Rockville, MD: Agency for Healthcare and Research Quality; Oct 2008. 2008.
12.
go back to reference Miller S, Steele S. Translational Research: Novel Molecular Screening Approaches in Colorectal Cancer. J Surg Oncol. 2012;105(5):459–67.CrossRefPubMed Miller S, Steele S. Translational Research: Novel Molecular Screening Approaches in Colorectal Cancer. J Surg Oncol. 2012;105(5):459–67.CrossRefPubMed
13.
go back to reference (CDC) CfDCaP. Use of colorectal cancer tests--United States, 2002, 2004, and 2006. MMWR Morb Mortal Wkly Rep. 2008;57(10):253. (CDC) CfDCaP. Use of colorectal cancer tests--United States, 2002, 2004, and 2006. MMWR Morb Mortal Wkly Rep. 2008;57(10):253.
14.
go back to reference Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007(1):CD001216. Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007(1):CD001216.
15.
go back to reference Shapiro J, Seeff L, Thompson T, et al. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1623–30.CrossRefPubMed Shapiro J, Seeff L, Thompson T, et al. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1623–30.CrossRefPubMed
16.
go back to reference (CDC) CfDCaP. Vital signs: colorectal cancer screening test use--United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(44):881. (CDC) CfDCaP. Vital signs: colorectal cancer screening test use--United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(44):881.
17.
go back to reference Meissner H, Breen N, Klabunde C, Vernon S. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15(2):389–94.CrossRefPubMed Meissner H, Breen N, Klabunde C, Vernon S. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15(2):389–94.CrossRefPubMed
18.
go back to reference Brounts L, Lehmann R, Lesperance K, et al. Improved rates of colorectal cancer screening in an equal access population. Am J Surg. 2009;197:609–13.CrossRefPubMed Brounts L, Lehmann R, Lesperance K, et al. Improved rates of colorectal cancer screening in an equal access population. Am J Surg. 2009;197:609–13.CrossRefPubMed
19.
go back to reference Hassan M, Arthurs Z, Sohn V, Steele S. Race does not impact colorectal cancer treatment or outcomes with equal access. Am J Surg. 2009;197:485–90.CrossRefPubMed Hassan M, Arthurs Z, Sohn V, Steele S. Race does not impact colorectal cancer treatment or outcomes with equal access. Am J Surg. 2009;197:485–90.CrossRefPubMed
20.
go back to reference Rex D, Johnson D, Lieberman D, et al. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroenterol. 2000;95:868–77.PubMed Rex D, Johnson D, Lieberman D, et al. Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. Am J Gastroenterol. 2000;95:868–77.PubMed
21.
go back to reference Rodgers Gr, Becker P, Bennett C, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008;6(6):536.PubMed Rodgers Gr, Becker P, Bennett C, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008;6(6):536.PubMed
22.
go back to reference Atkin W, Cuzick J, Northover J, Whynes D. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet. 1993;341(8847):736–40.CrossRefPubMed Atkin W, Cuzick J, Northover J, Whynes D. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet. 1993;341(8847):736–40.CrossRefPubMed
23.
go back to reference Mandel J, Church T, Bond J, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603–7.CrossRefPubMed Mandel J, Church T, Bond J, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603–7.CrossRefPubMed
24.
go back to reference Winawer S, Flehinger B, Schottenfeld D, Miller D. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst. 1993;85(16):1311–8.CrossRefPubMed Winawer S, Flehinger B, Schottenfeld D, Miller D. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst. 1993;85(16):1311–8.CrossRefPubMed
25.
go back to reference Agrawal S, Bhupinderjit A, Bhutani M, et al. Colorectal cancer in African Americans. Am J Gastroenterol. 2005;100:515–23.CrossRefPubMed Agrawal S, Bhupinderjit A, Bhutani M, et al. Colorectal cancer in African Americans. Am J Gastroenterol. 2005;100:515–23.CrossRefPubMed
26.
go back to reference Bastaini R, Gallardo N, Maxwell A. Barriers to colorectal screening among African Americans. J Psycho Oncol. 2001;19:113–32.CrossRef Bastaini R, Gallardo N, Maxwell A. Barriers to colorectal screening among African Americans. J Psycho Oncol. 2001;19:113–32.CrossRef
27.
go back to reference Goel M, Wee C, McCarthy E, et al. Racial and ethnic disparities in cancer screening: the importance of foreign birth as a barrier to care. J Gen Intern Med. 2003;18:1028–35.PubMedCentralCrossRefPubMed Goel M, Wee C, McCarthy E, et al. Racial and ethnic disparities in cancer screening: the importance of foreign birth as a barrier to care. J Gen Intern Med. 2003;18:1028–35.PubMedCentralCrossRefPubMed
28.
go back to reference Homayoon B, Shahidi N, Cheung W. Impact of Asian ethnicity on colorectal cancer screening: a population-based analysis. Am J Clin Oncol. 2013;36(2):167–73.CrossRefPubMed Homayoon B, Shahidi N, Cheung W. Impact of Asian ethnicity on colorectal cancer screening: a population-based analysis. Am J Clin Oncol. 2013;36(2):167–73.CrossRefPubMed
29.
go back to reference Reyes-Ortiz C, Eschbach K, Zhang D, Goodwin J. Neighborhood composition and cancer among Hispanics: tumor stage and size at diagnosis. Cancer Epidemiol Biomarkers Prev. 2008;17:2931–6.PubMedCentralCrossRefPubMed Reyes-Ortiz C, Eschbach K, Zhang D, Goodwin J. Neighborhood composition and cancer among Hispanics: tumor stage and size at diagnosis. Cancer Epidemiol Biomarkers Prev. 2008;17:2931–6.PubMedCentralCrossRefPubMed
30.
go back to reference Swan J, Breen N, Coates R, et al. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528–40.CrossRefPubMed Swan J, Breen N, Coates R, et al. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528–40.CrossRefPubMed
31.
go back to reference Theuer C, Wagner J, Taylor T, et al. Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the U.S. Gastroenterology. 2001;120:848–56.CrossRefPubMed Theuer C, Wagner J, Taylor T, et al. Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the U.S. Gastroenterology. 2001;120:848–56.CrossRefPubMed
32.
go back to reference Moiel D, Thompson J. Early detection of colon cancer - the Kaiser Permanente Northwest 30-year history: how do we measure success? Is it the test, the number of tests, the stage, or the percentage of screen-detected patients? The Permanente Journal. 2011;15(4):30–8.PubMedCentralCrossRefPubMed Moiel D, Thompson J. Early detection of colon cancer - the Kaiser Permanente Northwest 30-year history: how do we measure success? Is it the test, the number of tests, the stage, or the percentage of screen-detected patients? The Permanente Journal. 2011;15(4):30–8.PubMedCentralCrossRefPubMed
33.
go back to reference Bonelli L, Martines H, Conio M, et al. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case–control study. Int J Cancer. 1988;41:513–7.CrossRefPubMed Bonelli L, Martines H, Conio M, et al. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case–control study. Int J Cancer. 1988;41:513–7.CrossRefPubMed
35.
go back to reference Grossman S, Milos M. Colonoscopic screening of persons with suspected risk factors for colon cancer. Gastroenterology. 1988;94:395–400.PubMed Grossman S, Milos M. Colonoscopic screening of persons with suspected risk factors for colon cancer. Gastroenterology. 1988;94:395–400.PubMed
36.
go back to reference Gulliem G, Neugut A, Forde K, et al. Colonic neoplasms in asymptomatic first-degree relatives of colon cancer patients. Am J Gastroenterol. 1988;83:271–3. Gulliem G, Neugut A, Forde K, et al. Colonic neoplasms in asymptomatic first-degree relatives of colon cancer patients. Am J Gastroenterol. 1988;83:271–3.
37.
go back to reference Kune G, Kune S, Watson L. The Melbourne colorectal cancer study. Characterization of patients with a family history of colorectal cancer. Dis Colon Rectum. 1987;30:600–6.CrossRefPubMed Kune G, Kune S, Watson L. The Melbourne colorectal cancer study. Characterization of patients with a family history of colorectal cancer. Dis Colon Rectum. 1987;30:600–6.CrossRefPubMed
38.
go back to reference Maire P, Morichau-Beauchant M, Drucker J, et al. Familial prevalence of colorectal cancer. A 3-year case–control study. Gastroenterol Clin Biol. 1984;8:22–7.PubMed Maire P, Morichau-Beauchant M, Drucker J, et al. Familial prevalence of colorectal cancer. A 3-year case–control study. Gastroenterol Clin Biol. 1984;8:22–7.PubMed
39.
go back to reference Rozen P, Fireman Z, Figer A, et al. Family history of colorectal cancer as a marker of potential malignancy within a screening program. Cancer. 1987;60:248–54.CrossRefPubMed Rozen P, Fireman Z, Figer A, et al. Family history of colorectal cancer as a marker of potential malignancy within a screening program. Cancer. 1987;60:248–54.CrossRefPubMed
40.
go back to reference Rex D, Johnson D, Anderson J, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104(3):739–50.CrossRefPubMed Rex D, Johnson D, Anderson J, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104(3):739–50.CrossRefPubMed
Metadata
Title
Screening or Symptoms? How Do We Detect Colorectal Cancer in an Equal Access Health Care System?
Authors
Quinton M. Hatch
Kevin R. Kniery
Eric K. Johnson
Shelly A. Flores
David L. Moeil
John J. Thompson
Justin A. Maykel
Scott R. Steele
Publication date
01-02-2016
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 2/2016
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-3042-6

Other articles of this Issue 2/2016

Journal of Gastrointestinal Surgery 2/2016 Go to the issue